Brief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
14/10/2026 19:35
BRIEF-JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo Oct 14 (Reuters) - JCR Pharmaceuticals Co., Ltd. 4552.T:
JCR PHARMACEUTICALS RECEIVES MARKETING AUTHORIZATION IN KUWAIT FOR IZCARGO™, A BLOOD-BRAIN BARRIER-PENETRATING ENZYME REPLACEMENT THERAPY FOR HUNTER SYNDROME
JCR PHARMACEUTICALS CO. - TO SEEK MARKETING AUTHORIZATION FOR IZCARGO IN MENA REGION; TAIBA TO HANDLE SALES
JCR PHARMACEUTICALS CO.,.: IMPACT OF ANNOUNCEMENT ON JCR'S CONSOLIDATED FINANCIAL RESULTS FOR THIS FISCAL YEAR IS EXPECTED TO BE MINOR
((Reuters.Briefs@thomsonreuters.com;))
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results